NICE Single Technology Appraisal Guidance No 261 –
Rivaroxaban for the treatment of deep vein thrombosis and
prevention of recurrent deep vein thrombosis and pulmonary
embolism
This NICE guidance was published on 25 July
2012. The web reference for the appraisal and other related
documents is: www.nice.org.uk/TA261
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (755/12) on
this medication for this indication in January 2012. This stated
that:
rivaroxaban (Xarelto®) is
accepted for use within NHS Scotland.
Indication under review:
treatment of deep vein thrombosis (DVT), and prevention of
recurrent DVT and pulmonary embolism (PE) following an acute DVT in
adults.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 25 July 2012
